Articles published by Atara Biotherapeutics, Inc.
![](https://mms.businesswire.com/media/20240705905103/en/2170299/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20240702299482/en/2170309/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20240621317043/en/2166715/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20240617794969/en/2160683/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20240607147278/en/2144659/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20240605720457/en/2146032/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20240529973518/en/2144395/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20240520985176/en/2135080/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20240509763182/en/2126314/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20240503192785/en/2113326/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20240405217863/en/2087520/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20240328081178/en/2082470/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20240229015853/en/2049907/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20240228404331/en/2049233/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20240214963142/en/2034057/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20240131800324/en/2015453/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20240107077138/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20240107093705/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20240104354568/en/1987719/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20231220458866/en/1976254/5/Atara-Bio1_R_whtbox_3000px20190319.jpg)
![](https://mms.businesswire.com/media/20231209652704/en/1965149/5/Atara-Bio1_logo_300x300.jpg)
![](https://mms.businesswire.com/media/20231130548164/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20231129702180/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20231121525276/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
November 22, 2023
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20231109837801/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
November 10, 2023
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20231108902565/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20231031702630/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20230918233480/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20230919197771/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
September 19, 2023
Via Business Wire
Tickers
ATRA
![](https://mms.businesswire.com/media/20230830304194/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023
Via Business Wire
Tickers
ATRA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.